Dan Whittam supports clients with research and analysis spanning a variety of healthcare sectors and stakeholders.

He applies his background in clinical operations research, health IT analysis, and ACA implementation to advise clients on a range of policy issues.

Prior to joining Avalere, Dan was a senior consultant at Booz Allen Hamilton where, as marketplace system integrator for the Centers for Consumer Information and Issuer Oversight, CMS, he coordinated stakeholder interactions to facilitate development and maintenance of Healthcare.gov. In addition, he provided program support and research and analysis to the Veterans Affairs Center for Innovation, developing business cases around value proposition based on clinical, operational, and patient safety improvements.

Dan has a BA in political science and English from Williams College.

Authored Content


New Avalere analysis finds that practices currently participating in the Oncology Care Model (OCM) would be more likely to receive a Novel Therapy Adjustment (NTA) in the newly proposed Oncology Care First (OCF) Model.

Avalere analysis finds that, despite substantial list price decreases across the PCSK9 inhibitor class, out-of-pocket costs for the majority of 2020 Part D beneficiaries remain significant

New research from Avalere finds that capped funding policies could reduce federal funding to states, specifically for children, by $89B to $163B nationally for FY 2020–2029.

A new Avalere analysis finds that oncology practices participating in the Oncology Care Model (OCM) treated patients with 2–3% higher Medicare costs per episode, on average, than OCM prediction model estimates during the first two performance periods.

Pressure to lower costs will increase for OCM providers as CMS pushes to 2-sided risk.